Biotech
Health
Melbourne biotech signs US cancer deal for its engineered immune cells
Melbourne-based Cartherics executed a research collaboration and option agreement with the Zucker Institute, the commercialisation entity for the Medical University of South Carolina, on 1 September 2026.